A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Systemic Sclerosis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Local Institution - 0035, Scottsdale, Arizona, United States

  • University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

    Contact: Study coordinator (Melissa Griffith) · 720-848-7700
  • Local Institution - 0001, Denver, Colorado, United States

  • Local Institution - 0069, Miami, Florida, United States

  • Emory University School of Medicine, Atlanta, Georgia, United States

    Contact: Study coordinator (Arezou Khosroshahi) · 404-778-6638
  • Local Institution - 0139, Chicago, Illinois, United States

  • Local Institution - 0084, Worcester, Massachusetts, United States

  • Local Institution - 0034, Ann Arbor, Michigan, United States

  • Local Institution - 0037, Rochester, Minnesota, United States

  • Local Institution - 0082, Summit, New Jersey, United States

  • Local Institution - 0122, Cleveland, Ohio, United States

  • Local Institution - 0142, Philadelphia, Pennsylvania, United States

  • Local Institution - 0143, Pittsburgh, Pennsylvania, United States

  • Local Institution - 0002, Charleston, South Carolina, United States

  • Local Institution - 0074, Dallas, Texas, United States

  • Local Institution - 0144, Houston, Texas, United States

  • Local Institution - 0008, Seattle, Washington, United States

  • Local Institution - 0057, Leuven, Vlaams-Brabant, Belgium

  • Local Institution - 0080, Liège, Belgium

  • Local Institution - 0104, Halifax, Nova Scotia, Canada

  • Local Institution - 0088, Sherbrooke, Quebec, Canada

  • Local Institution - 0031, Strasbourg, Alsace, France

  • Local Institution - 0061, Toulouse, Haute-Garonne, France

  • Local Institution - 0049, Bordeaux, France

  • Local Institution - 0012, Bron, France

  • Local Institution - 0052, Paris, France

  • Local Institution - 0141, Rennes, France

  • Local Institution - 0046, Berlin, Germany

  • Local Institution - 0016, Cologne, Germany

  • Local Institution - 0028, Erlangen, Germany

  • Local Institution - 0042, Leipzig, Germany

  • Local Institution - 0032, München, Germany

  • Local Institution - 0033, Tübingen, Germany

  • Local Institution - 0038, Würzburg, Germany

  • Local Institution - 0103, Rome, Lazio, Italy

  • Local Institution - 0004, Milan, Milano, Italy

  • Local Institution - 0108, Pisa, Tuscany, Italy

  • Local Institution - 0106, Milan, Italy

  • Local Institution - 0026, Sapporo, Hokkaido, Japan

  • Local Institution - 0132, Yokohama, Kanagawa, Japan

  • Local Institution - 0137, Suita, Osaka, Japan

  • Local Institution - 0117, Bunkyo-ku, Tokyo, Japan

  • Local Institution - 0123, Fukuoka, Japan

  • Local Institution - 0136, Maebashi, Japan

  • Local Institution - 0118, Okayama, Japan

  • Local Institution - 0129, A Coruña, A Coruña [La Coruña], Spain

  • Local Institution - 0138, Barcelona, Catalunya [Cataluña], Spain

  • Local Institution - 0060, Barcelona, Spain

  • Local Institution - 0009, Málaga, Spain

  • Local Institution - 0047, Basel, Switzerland

  • Local Institution - 0068, Bern, Switzerland

  • Local Institution - 0078, Zurich, Switzerland

  • Local Institution - 0140, London, London, City of, United Kingdom

  • Local Institution - 0063, Leeds, West Yorkshire, United Kingdom

  • Local Institution - 0091, Sheffield, Yorkshire and the Humber, United Kingdom

  • Local Institution - 0059, London, United Kingdom

מובילי המחקר
  • Bristol-Myers Squibb

    Study Director

    Bristol-Myers Squibb